A phase II multicentre, open-label, proof-of-concept study of tasquinimod in hepatocellular, ovarian, renal cell, and gastric cancers.
Escudier, B Faivre, S Van Cutsem, E Germann, N Pouget, J Plummer, R Vergote, I Thistlethwaite, Fiona C Bjarnason, G Jones, R
Escudier, B
Faivre, S
Van Cutsem, E
Germann, N
Pouget, J
Plummer, R
Vergote, I
Thistlethwaite, Fiona C
Bjarnason, G
Jones, R
Citations
Altmetric:
Abstract
Tasquinimod is a small molecule with immunomodulatory, anti-angiogenic, and anti-metastatic properties that targets the tumor microenvironment. This study aimed to obtain a clinical proof of concept that tasquinimod was active and tolerable in patients with advanced solid tumors.
Description
Date
2017-08-10
Publisher
Collections
Keywords
Type
Article
Citation
A phase II multicentre, open-label, proof-of-concept study of tasquinimod in hepatocellular, ovarian, renal cell, and gastric cancers. 2017 Target Oncol